Pulse glucocorticoid therapy: The 'big shot' revisited

Archives of Dermatology

Volumn 132, Issue 12, 1996, Pages 1499-1502

  Roujeau, Jean Claude ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID;

BODY WEIGHT; DERMATOLOGY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; REMISSION; REVIEW; SKIN DISEASE; STEROID THERAPY;

EID: 0030459454     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.132.12.1499     Document Type: Review

References (37)

1. Gallant C, Kenny P. Oral glucocorticoids and their complications. J Am Acad Dermatol. 1986;14: 161-177.
2. The big shot. Lancet. 1977;309:633-634. Editorial.
3. White KP, Driscoll MS, Rothe MJ, Grant-Kels JM. Severe adverse cardiovascular effects of pulse steroid therapy: is continuous monitoring necessary? J Am Acad Dermatol. 1994;30:768-773.
4. Fine J-D, Appel ML, Green LK, Sams WM. Pemphigus vulgaris, combined treatment with intravenous corticosteroid pulse therapy, plasmapheresis, and azathioprine. Arch Dermatol. 1988; 124:236-239.
5. Pasricha JS, Thanzama J, Khan UK. Intermittent high-dose dexamethasone-cyclophosphamide therapy for pemphigus. Br J Dermatol. 1988; 119:73-77.
6. Kaur S, Kanwar AJ. Dexamethasone-cyclophosphamide pulse therapy in pemphigus. Int J Dermatol. 1990;29:371-374.
7. Pasricha JS, Das SS. Curative effect of dexamethasone-cyclophosphamide pulse therapy for the treatment of pemphigus vulgaris. Int J Dermatol. 1992;31:875-877.
8. Chryssomallis A, Dimitriades A, Chaidemenos GC, Panagiotides O, Karakatsanis G. Steroid-pulse therapy in pemphigus vulgaris, long term followup, Int J Dermatol. 1995;34;438-442.
9. Werth VP. Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. Arch Dermatol. 1998;132:1435-1439.
10. Bystryn J-C, Steiman NM. The adjuvant therapy of pemphigus: an update. Arch Dermatol. 1996; 132:203-212.
11. Carson PJ, Hameed A, Ahmed AR. Influence of treatment on the clinical course of pemphigus vulgaris. J Am Acad Dermatol. 1996;34:645-652.
12. Narang PK, Wilder R, Chatterji DC, Yeager RL, Gallelli JF. Systemic bioavailability and pharmacokinetics of methylprednisolone in patients with rheumatoid arthritis following 'high-dose' pulse administration. Biopharm Drug Dispos. 1983;4: 233-248.
13. Hayball PJ, Cosh DG, Ahern MJ, Schultz DW, Roberts-Thomson PJ. High dose oral methylprednisolone in patients with rheumatoid arthritis: pharmacokinetics and clinical response. Eur J Clin Pharmacol. 1992;42:85-88.
14. Alam SM, Kyriakides T, Lawden M, et al. Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry. 1993;56:1219-1220.
15. Meier CA. Mechanisms of immunosuppression by glucocorticoids. Eur J Endocrinol. 1996;134:50.
16. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NFκB activity through induction of IκB synthesis. Science. 1995;270:286-290.
17. Knudsen PJ, Dinarello CA, Strom TB. Glucocorticoids inhibit transcriptional and post-transcriptional expression of interleukin 1 in U937 cells. J Immunol. 1987;139:4129-4134.
18. Almawi WY, Lipman ML, Stevens AC, Zanker B, Hadro ET, Strom TB. Abrogation of glucocorticosteroid-mediated inhibition of T cell proliferation by the synergistic action of IL-1, IL-6, and IFN-γ. J Immunol. 1991;146:3523-3527.
19. Fan PT, Yu DTY, Targoff C, Bluestone R. Effect of corticosteroids on the human immune response: suppression of mitogen-induced lymphocyte proliferation by pulse methylprednisolone. Transplantation. 1978;26:266-267.
20. Hashimoto K, Shafran KM, Weber PS, Lazarus GS, Singer KH. Anti-cell surface pemphigus autoantibody stimulates plasminogen activator activity of human epidermal cells: a mechanism for the loss of epidermal cohesion and blister formation. J Exp Med. 1983;157:259-272.
21. Swanson DL, Dahl M. Methylprednisolone inhibits pemphigus acantholysis in skin cultures. J Invest Dermatol. 1983;81:258-260.
22. Bone RC, Fisher CJ, Clemmer TP, et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987;317:653-658.
23. Guillain-Barré Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet. 1993; 341:586-590.
24. Touraine JL, Traeger J. Mode of administration of steroids in treatment of renal-allograft rejection. Lancet. 1978;311:607.
25. Kauffman HM, Stromstad SA, Sampson D, Stawicki AT. Randomized steroid therapy of human kidney transplant rejection. Transplant Proc, 1979;11:36-38.
26. Park GD, Bartucci M, Smith MC. High versus low-dose methylprednisolone for acute rejection episodes in renal transplantation. Nephron. 1984; 36:80-83.
27. Hricik DE, Almawi WY, Strom TB. Trends in the use of glucocorticoids in renal transplantation. Transplantation. 1994;57:979-989.
28. Cathcart ES, Idelson BA, Scheinberg MA, Couser WG. Beneficial effects of methylprednisolone 'pulse' therapy in diffuse proliferative lupus nephritis. Lancet. 1976;307:163-166.
29. Edwards JCW, Snaith ML, Isenberg DA. A double blind controlled trial of methylprednisolone infusions in systemic lupus erythematosus using individualised outcome assessment. Ann Rheum Dis. 1987;46:773-776.
30. McFadden ER. Dosages of corticosteroids in asthma. Am Rev Respir Dis. 1993;147:1306-1310.
31. Visher TL, Sinniger M, Ott H, Gerster JC. A randomized, double blind trial comparing a pulse of 1000 with 250 mg methylprednisolone in rheumatoid arthritis. Clin Rheumatol. 1986;5:325-326.
32. Radia M, Furst DE. Comparison of three pulse methylprednisolone regimens in the treatment of rheumatoid arthritis. J Rheumatol. 1988;15: 242-246.
33. Iglehart IW, Sutton JD. Bender JC, et al. Intravenous pulse steroids in rheumatoid arthritis: a comparative dose study. J Rheumatol. 1990;17: 159-162.
34. Ferraz MB, Visioni RA, Oliveira LM, Ciconelli RM, Atra E. Intravenous methylprednisolone therapy in rheumatoid arthritis: a comparative dose study. Scand J Rheumatol. 1992;21:260-261.
35. Griffiths TD, Newman PK. Steroids in multiple sclerosis. J Clin Pharm Ther. 1994;19:219-222.
36. Beck RW, Cleary PA, Trobe JD, et al. The effects of steroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med. 1993;329:1764-1769.
37. Chrousos GA, Kattah JC, Beck RW, Cleary PA, and the Optic Neuritis Study Group. Side effects of glucocorticoid treatment: experience of the Optic Neuritis Treatment Trial. JAMA. 1993; 269:2110-2112.